Carvedilol and Hypertransaminasaemia - a phase IV clinical study of FDA data

Summary:

Hypertransaminasaemia is reported as a side effect among people who take Carvedilol (carvedilol), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Paclitaxel, and have Dyslipidaemia.

The phase IV clinical study analyzes which people have Hypertransaminasaemia when taking Carvedilol. It is created by eHealthMe based on reports of 110,224 people who have side effects when taking Carvedilol from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,649 Carvedilol users. Check the latest studies of Carvedilol.

What is Hypertransaminasaemia?

Hypertransaminasaemia is found to be associated with 358 drugs and 395 conditions by eHealthMe. Check the latest studies of Hypertransaminasaemia.

On Jul, 12, 2026

110,224 people reported to have side effects when taking Carvedilol.
Among them, 24 people (0.02%) have Hypertransaminasaemia.

Could Carvedilol cause Hypertransaminasaemia?

Among these 24 people:

How long have people been on Carvedilol when they have Hypertransaminasaemia? *

What is the gender of people who have Hypertransaminasaemia when taking Carvedilol? *

female: 95.65 %
male: 4.35 %

What is the age of people who have Hypertransaminasaemia when taking Carvedilol? *

What are other drugs people take besides Carvedilol? *

What are other side effects people have besides Hypertransaminasaemia? *

Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 9 people, 37.50%
Diarrhea: 8 people, 33.33%
Blood Creatinine Increased: 2 people, 8.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 8.33%
Thrombocytopenia (decrease of platelets in blood): 1 person, 4.17%
Skin Discoloration: 1 person, 4.17%
Skin Blushing/flushing (a sudden reddening of the face, neck): 1 person, 4.17%
Pneumonia: 1 person, 4.17%
Oedema (fluid collection in tissue): 1 person, 4.17%
Liver Injury: 1 person, 4.17%

What are the existing conditions these people have? *

Dyslipidaemia (abnormal amount of lipids): 9 people, 37.50%
Pain: 7 people, 29.17%
Breast Cancer Metastatic: 5 people, 20.83%
Breast Cancer: 4 people, 16.67%
Sedation: 1 person, 4.17%
Hypertriglyceridaemia (excess of triglycerides in the blood): 1 person, 4.17%
Hepatocellular Carcinoma (liver cancer): 1 person, 4.17%
Dry Eyes (lack of adequate tears): 1 person, 4.17%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 4.17%
Basal Cell Carcinoma (a skin cancer, it rarely metastasizes or kills): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and have Hypertransaminasaemia?

- Check whether Hypertransaminasaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carvedilol:

Carvedilol (112,649 reports)

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypertransaminasaemia:

Hypertransaminasaemia (358 drugs)

Browse all the conditions that are associated with Hypertransaminasaemia:

Hypertransaminasaemia (395 conditions)

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .
Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol (the active ingredients of Carvedilol) and Carvedilol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.